+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 124 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the use of delgocitinib cream applied twice daily to treat adults with mild to severe lichen sclerosus LS, focusing mainly on female participants since LS is more common in females. This Phase 3 trial is designed to assess the efficacy and safety of delgocitinib in comparison to a cream vehicle over a long period. The study includes two parts Part 1 enrolls females to determine the best dose, and Part 2 enrolls both males and females to further evaluate safety and efficacy. Participants will be assigned randomly to receive either delgocitinib cream at specified doses or a cream vehicle. Treatments are applied twice daily during an initial 12-week period followed by a continuation treatment period lasting 40 weeks. Various dosing regimens are used across groups, including delgocitinib cream alone, cream vehicle alone, or combinations transitioning between the two during the study. Male participants will be included in a substudy to evaluate delgocitinibs effects in men. During the trial, participants will attend clinic visits and undergo assessments including measurement of skin condition severity using the IGA-LS score, clinical lichen sclerosus score CLISSCO, and patient-reported scales for skin pain and itch. Quality of life related to vulvar symptoms will also be monitored. Safety is carefully tracked through adverse event reporting and laboratory tests throughout the study, which lasts from 55 to 60 weeks per participant. The primary outcome is the number of participants achieving a specific improvement in LS severity at week 12.

Age: 18Years +All GendersPhase 3
33 locations
A

Actively Recruiting

Researchers are investigating treatments for hormone receptor-positive and HER2-negative breast cancer that is either locally advanced and cannot be removed by surgery or has spread to other body parts. The study focuses on comparing patritumab deruxtecan with chemotherapy or trastuzumab deruxtecan to see if patients live longer or have delayed cancer progression. This phase 3 trial evaluates these treatments in people who have had prior progression on CDK46 inhibitor plus endocrine therapy. Participants receive either patritumab deruxtecan through intravenous infusion every three weeks for about 13 months or treatment chosen by their doctor, which may include various chemotherapy drugs or trastuzumab deruxtecan up to 13 months. Treatments are given in cycles with specific dosing schedules depending on the drug selected. Rescue medications are also allowed as needed following approved guidelines. During the study, participants undergo regular assessments including scans to measure disease progression and evaluations of quality of life using standardized questionnaires. Researchers monitor overall survival and progression-free survival for up to 85 months. Safety is closely followed by recording adverse events and treatment discontinuations. The trial aims to provide detailed data on how these treatments affect patients over time and their impact on symptoms and functioning.

Age: 18Years +All GendersPhase 3
206 locations
I

Actively Recruiting

Researchers are studying the best steroid dose to treat acute T cell mediated rejection TCMR in people who have had kidney or kidney-pancreas transplants. TCMR is a type of rejection where the bodys immune system attacks the transplanted organ, which can cause serious complications or organ failure. This international, multi-center trial aims to find the lowest effective and safe steroid dose to manage this condition, addressing a long-standing question in transplant care. The trial compares four treatment approaches that differ in doses of intravenous methylprednisolone IV MP and oral prednisone taper. Participants receive either a high or low dose of IV MP for three days followed by a high or low dose of oral prednisone for seven days, then return to standard prednisone. This factorial design allows evaluation of both drugs dose effects. The study is sponsored by the University of Sydney and involves collaboration among several international transplant societies. Participants will be closely monitored with biopsies and blood tests to assess rejection resolution and kidney function over 12 weeks. Researchers will also track survival, kidney filtration rates, urine protein levels, infection rates, quality of life, and other health outcomes up to 48 weeks. The study includes regular visits and evaluations to ensure safety and collect data on treatment effects and side effects during the trial period.

Age: 2Years +All GendersPhase 3
30 locations
E

Actively Recruiting

Researchers are evaluating the effects of camoteskimab in adults aged 18 to 65 with moderate-to-severe atopic dermatitis. This phase 2b, multicenter, randomized, double-blind, placebo-controlled study aims to assess the efficacy and safety of camoteskimab compared to placebo. Participants include those who are treatment-naive or have had an inadequate response to previous biologic therapies. The study has two parts Part 1 is a 24-week placebo-controlled period where participants are randomly assigned to one of three camoteskimab dose levels or placebo, all administered by subcutaneous injection. In Part 2, an extension period, all participants receive camoteskimab. This design allows comparison of different dose levels and monitoring of long-term treatment effects. Participants will be assessed regularly throughout the study with measures including the Eczema Area and Severity Index EASI, Investigator Global Assessment IGA, and peak pruritus numerical rating scale PP-NRS. Safety and efficacy will be monitored through these assessments over 24 weeks and beyond. The study includes signing informed consent and adherence tracking, with the primary outcome focused on percentage change in EASI score from baseline to Week 24.

Age: 18Years - 65YearsAll GendersPhase 2
85 locations
D

Actively Recruiting

Researchers are studying the effects of durvalumab, an immunotherapy drug, on various types of advanced or metastatic solid tumors in patients who have previously stopped checkpoint therapy due to immune-related side effects. They are also evaluating whether prednisone, a steroid, can help reduce these side effects when given with durvalumab. Additionally, the study allows patients from completed Canadian Cancer Trials Group CCTG trials to continue treatment with durvalumab, with or without tremelimumab. Participants receive durvalumab intravenously every four weeks, with prednisone given orally during the first two cycles to assess its impact on side effects. Some patients may also continue treatment with tremelimumab alongside durvalumab, depending on their previous trial enrollment. The study includes two substudies one focusing on patients who discontinued prior immunotherapy due to toxicity, and another allowing continued treatment for those already enrolled in completed CCTG trials. Throughout the study, participants undergo regular monitoring including laboratory tests and imaging to track disease status and side effects. Researchers record the number and severity of adverse events over two years, as well as treatment responses and the effectiveness of corticosteroids in preventing immune-related side effects. Patients are followed closely for treatment safety and efficacy, with a minimum life expectancy of 12 weeks required for participation.

Age: 18Years +All GendersPhase 2
11 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of Datopotamab Deruxtecan Dato-DXd with or without durvalumab compared to chemotherapy chosen by doctors combined with pembrolizumab in people with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer TNBC. This Phase III international study aims to see if Dato-DXd plus durvalumab can help patients live longer without their cancer worsening or improve overall survival, while also assessing impacts on quality of life. Participants are randomly assigned to one of three groups Dato-DXd with durvalumab, a chemotherapy option paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin combined with pembrolizumab, or Dato-DXd alone. All study drugs are given by intravenous infusion. The study will monitor patients for disease progression and response, with treatments and evaluations continuing for up to about 33 months. During the study, participants will undergo regular assessments including tumor measurements by imaging using RECIST 1.1 criteria, survival tracking, and quality of life evaluations focused on symptoms like breast and arm pain and physical functioning. Safety and drug effects will also be closely monitored throughout treatment and follow-up. The total study participation may last several years, with some outcomes measured up to 64 months from randomization.

Age: 18Years +All GendersPhase 3
318 locations
R

Actively Recruiting

Researchers are evaluating radiation treatments for women with small, node-negative invasive breast cancer measuring 3 cm or less. This trial compares partial breast irradiation PBI to whole breast irradiation WBI, both given once daily over about one week after breast-conserving surgery. The main goal is to see if PBI is not worse than WBI for preventing local cancer recurrence and if it improves cosmetic outcomes, as judged by patients, three years after treatment. Participants are randomly assigned to receive either PBI or WBI. Both groups receive a total radiation dose of 26 Gy split into five daily treatments over 5 to 7 days, with a possible extension to 8 days due to scheduling. The WBI targets the entire breast, while PBI focuses radiation on the tumor bed plus a margin of normal tissue. Patients are not informed which treatment they receive to avoid bias in assessing cosmetic results. Key factors such as tumor size, estrogen receptor status, and treatment center are used for group assignment. During the study, participants will be monitored annually for five years to assess local recurrence, distant disease-free survival, overall survival, and radiation side effects. Cosmetic outcomes will be evaluated by both patients and clinical staff at 3 and 5 years. Quality of life will also be measured at multiple time points. The study lasts several years, with primary outcomes assessed at three years and continued follow-up through at least five years post-treatment.

Age: 50Years - 120YearsFEMALEPhase 3
31 locations
C

Actively Recruiting

Researchers are comparing two treatment combinations for adults with advanced nonsquamous non-small cell lung cancer NSCLC that is stage IV or advanced stage IIIBC, specifically with a KRAS p.G12C mutation and no PD-L1 expression. The study evaluates progression-free survival and overall survival between participants receiving sotorasib with chemotherapy and those receiving pembrolizumab with chemotherapy. This is a phase 3, randomized, open-label study aiming to find which frontline therapy might better manage this type of lung cancer. Participants are randomly assigned to one of two groups one group receives sotorasib orally combined with carboplatin and pemetrexed chemotherapy, and the other group receives pembrolizumab given intravenously combined with the same chemotherapy agents. Treatments are given as front-line therapy for their cancer. The study measures the effects of these combinations over time, including tumor response and quality of life changes. During the study, participants will be closely monitored for progression-free survival, overall survival, and other outcomes related to tumor response and quality of life through questionnaires. Researchers will track treatment-emergent adverse events, vital signs, and lab tests to evaluate safety. The study includes follow-up assessments for up to approximately 5.5 years, allowing comprehensive evaluation of long-term outcomes and side effects. Participant involvement includes regular visits for treatment administration and assessments throughout the study period.

Age: 18Years - 100YearsAll GendersPhase 3
424 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of divarasib combined with pembrolizumab compared with pembrolizumab plus pemetrexed and carboplatin or cisplatin for adults with KRAS G12C-mutated, advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have not received prior treatment. This phase 3 randomized study aims to find the best first-line therapy option for this specific lung cancer type. Participants are randomly assigned to one of two groups one group receives divarasib orally once daily and pembrolizumab through intravenous infusion every three weeks, while the other group receives pembrolizumab, pemetrexed, and carboplatin or cisplatin all by intravenous infusion every three weeks. The study treatments are given as first-line therapy, and participants are monitored for up to approximately five years. During the study, participants undergo regular assessments including scans to measure tumor response, evaluations of lung cancer symptoms like cough and breathlessness, quality of life questionnaires, and monitoring for side effects. Researchers track progression-free survival and overall survival for up to about five years. Safety and symptom severity are closely followed throughout the study, providing comprehensive data on treatment impact and participant well-being.

Age: 18Years +All GendersPhase 3
288 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of different doses of Pirtobrutinib in adults with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. Part 1 of the study focuses on participants who have received one to three prior treatments, including a covalent Bruton tyrosine kinase BTK inhibitor, while Part 2 studies treatment-nave participants with a specific genetic deletion 17p deletion. This trial is a Phase 2, open-label, randomized study sponsored by Loxo Oncology, Inc. Participants receive Pirtobrutinib orally in varying doses. In Part 1, three different doses are tested in participants with relapsed or refractory CLLSLL who have prior BTK inhibitor treatment. Part 2 evaluates Pirtobrutinib monotherapy at a standard dose in treatment-nave participants with 17p deletions. The study uses a parallel design with random assignment to treatment groups. Participants are involved for approximately three years in Part 1 and up to two years in Part 2. Researchers monitor overall response rate as the primary outcome, along with duration of response over this time. Participants must be able to swallow oral medication and have their health status regularly assessed, including physical performance scores. Safety and treatment effects are followed throughout the study period.

Age: 18Years +All GendersPhase 2
129 locations

1-10 of 124

1